Abstract 52P
Background
Lung cancer's multiple resistance to tyrosine kinase inhibitors is inexorable and often unexplained in many NSLCs with EGFR mutations or other oncogenes and epigenetic changes. This suggests the need for new treatment strategies.
Methods
We generated second-generation CD28-costimulated EGFR-specific CAR constructs using lentiviral vectors to modify NK92 cells. We evaluated the utility of NK92 cells expressing a CAR-EGFR against TKI-resistant lung cancer cells at a low effector-to-target ratio to allow possible escape or evolution of select lung cancer cells. EGFR expression was analyzed by flow cytometry.
Results
We evaluated the utility of NK92 cells expressing a CAR-EGFR against TKI-resistant lung cancer cells. Our approach used a low effector-to-target ratio to allow possible escape or evolution of select lung cancer cells. We found that Gefitinib-resistant lung cancer cells HCC827GR6 and TKI-sensitive HCC827 are equally attacked by NK92 cells. However, TKI-resistant HCC827GR6 were more sensitive to EGFR-CAR NK cell attacks than parental HCC827. Predictably, EGFR-CAR NK cell attacks led to reduced EGFR expression in HCC827 and growth without increasing resistance to naïve NK92 attacks. However, the EGFR-CAR NK cell attack caused an increase in EGFR expression in gefitinib-resistant HCC827GR6 cells with a slight reduction in growth. This paradoxical increased EGFR protein expression suggests a positive selection of mutant EGFR, reducing their chance of escaping new EGFR-CAR NK cell attacks. Indeed, in co-culture experiments of TKI-sensitive and TKI-resistant cells, the latter were more efficiently eliminated, suggesting the preferential killing of TKI-resistant lung cancer cells by EGFR-CAR NK.
Conclusions
Our data indicate that TKI-resistant lung cancer cells, which evolved to depend on the expression of a mutated EGFR, are targeted more efficiently by EGFR-CAR NK cells than TKI-sensitive cells.
Legal entity responsible for the study
Sumei Chen and Youssef Jounaidi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display